This article was originally published in The Gray Sheet
Plans first quarter 1994 worldwide launch of its AxSym random, continuous and immediate access immunoassay analyzer and Maestro data management system, which allows "the integration of up to eight analyzers." Abbott announced development of AxSym in November 1992 ("The Gray Sheet" Nov. 16, 1992, p. 11). The two devices were previewed at an American Association for Clinical Chemistry meeting in New York. Shipments are to begin following FDA clearance of assays for the analyzer, which was okayed for marketing in 1992. The AxSym will list for about $124,000, and the Maestro will carry a price of "just over $38,000".
You may also be interested in...
Regulatory review resource-intensive cell and gene therapy licensing applications are rolling toward US FDA along expedited pathways, while complete response letters and missed goal dates start to stack up under pandemic inspection constraints.
With Warp Speed Decisions Already Made, Transitioning To Biden Admin Should Be No Trouble, Slaoui Says
As vaccines near availability, Moncef Slaoui says his full-time role at OWS may be ending. He has not met with the Biden Transition team, but notes that other Warp Speed officials have.
Strong top-line efficacy in pyruvate kinase deficiency patients who don’t receive regular transfusions looks approvable, analysts say, but Agios will await data in regularly transfused patients.